Novo’s Wegovy pill helps patients lose about 6% of weight in three months, real-world data show

Summary

• Novo Nordisk's daily oral Wegovy pill resulted in an average 6.2% body weight loss over three months based on real-world data presented at the ObesityWeek conference.
• Study participants taking the pill between January 5 & February 7, 2026, lost an average of 6.3 kg (13.9 pounds) from a baseline of 103.0 kg (227 pounds).
• Approximately 60% of the 5,872 adults on the Ro telehealth platform lost at least 5% of their weight, while roughly one in six lost at least 10%.
• Novo Nordisk aims to regain market share lost to Eli Lilly in the obesity treatment race with this oral alternative to its injectable Wegovy.
• Oral treatments now account for roughly one-third of U.S. obesity prescriptions, with Novo securing over 80% of new oral prescriptions.
• Separate real-world data indicates patients switching from injections to the oral pill continued to lose weight.
• Long-term studies show oral Wegovy led to a 14% weight reduction over 64 weeks, compared to an 11% reduction over 72 weeks for Eli Lilly's Foundayo.
• Novo Nordisk's stock has fallen over 70% from its peak as Eli Lilly surpassed it to lead the obesity-drug market.